Literature DB >> 33551817

The Impact of Cannabidiol on Human Brain Function: A Systematic Review.

Albert Batalla1, Julian Bos1, Amber Postma1, Matthijs G Bossong1.   

Abstract

Background: Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-to-date systematic literature overview of neuroimaging studies that investigated the acute impact of CBD on human brain function.
Methods: Papers published until May 2020 were included from PubMed following a comprehensive search strategy and pre-determined set of criteria for article selection. We included studies that examined the effects of CBD on brain function of healthy volunteers and individuals diagnosed with a psychiatric disorder, comprising both the effects of CBD alone as well as in direct comparison to those induced by ∆9-tetrahydrocannabinol (THC), the main psychoactive component of Cannabis.
Results: One-ninety four studies were identified, of which 17 met inclusion criteria. All studies investigated the acute effects of CBD on brain function during resting state or in the context of cognitive tasks. In healthy volunteers, acute CBD enhanced fronto-striatal resting state connectivity, both compared to placebo and THC. Furthermore, CBD modulated brain activity and had opposite effects when compared to THC following task-specific patterns during various cognitive paradigms, such as emotional processing (fronto-temporal), verbal memory (fronto-striatal), response inhibition (fronto-limbic-striatal), and auditory/visual processing (temporo-occipital). In individuals at clinical high risk for psychosis and patients with established psychosis, acute CBD showed intermediate brain activity compared to placebo and healthy controls during cognitive task performance. CBD modulated resting limbic activity in subjects with anxiety and metabolite levels in patients with autism spectrum disorders.
Conclusion: Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder. This included modulation of functional networks relevant for psychiatric disorders, possibly reflecting CBD's therapeutic effects. Future studies should consider replication of findings and enlarge the inclusion of psychiatric patients, combining longer-term CBD treatment with neuroimaging assessments.
Copyright © 2021 Batalla, Bos, Postma and Bossong.

Entities:  

Keywords:  Cannabis (marijuana); cannabidiol; delta9-tetrahydrocannabinol; functional MRI; neuroimaging

Year:  2021        PMID: 33551817      PMCID: PMC7858248          DOI: 10.3389/fphar.2020.618184

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  65 in total

Review 1.  A systematic review of the antipsychotic properties of cannabidiol in humans.

Authors:  Tabitha A Iseger; Matthijs G Bossong
Journal:  Schizophr Res       Date:  2015-02-07       Impact factor: 4.939

2.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

3.  Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.

Authors:  Matthew B Wall; Rebecca Pope; Tom P Freeman; Oliwia S Kowalczyk; Lysia Demetriou; Claire Mokrysz; Chandni Hindocha; Will Lawn; Michael Ap Bloomfield; Abigail M Freeman; Amanda Feilding; David Nutt; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2019-04-23       Impact factor: 4.153

Review 4.  Cannabidiol: State of the art and new challenges for therapeutic applications.

Authors:  Simona Pisanti; Anna Maria Malfitano; Elena Ciaglia; Anna Lamberti; Roberta Ranieri; Gaia Cuomo; Mario Abate; Giorgio Faggiana; Maria Chiara Proto; Donatella Fiore; Chiara Laezza; Maurizio Bifulco
Journal:  Pharmacol Ther       Date:  2017-02-22       Impact factor: 12.310

5.  Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.

Authors:  Rodolphe Nenert; Jane B Allendorfer; E Martina Bebin; Tyler E Gaston; Leslie E Grayson; James T Houston; Jerzy P Szaflarski
Journal:  Epilepsy Behav       Date:  2020-07-31       Impact factor: 2.937

Review 6.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

Authors:  Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2013-06-27       Impact factor: 79.321

7.  [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.

Authors:  H Donald Burns; Koen Van Laere; Sandra Sanabria-Bohórquez; Terence G Hamill; Guy Bormans; Wai-si Eng; Ray Gibson; Christine Ryan; Brett Connolly; Shil Patel; Stephen Krause; Amy Vanko; Anne Van Hecken; Patrick Dupont; Inge De Lepeleire; Paul Rothenberg; S Aubrey Stoch; Josee Cote; William K Hagmann; James P Jewell; Linus S Lin; Ping Liu; Mark T Goulet; Keith Gottesdiener; John A Wagner; Jan de Hoon; Luc Mortelmans; Tung M Fong; Richard J Hargreaves
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

8.  Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.

Authors:  Toby T Winton-Brown; Paul Allen; Sagnik Bhattacharyya; Sagnik Bhattacharrya; Stefan J Borgwardt; Paolo Fusar-Poli; Jose A Crippa; Marc L Seal; Rocio Martin-Santos; Dominic Ffytche; Antonio W Zuardi; Zerrin Atakan; Philip K McGuire
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

Review 9.  Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.

Authors:  Marco Colizzi; Sagnik Bhattacharyya
Journal:  Curr Addict Rep       Date:  2017-04-29

10.  Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Authors:  Sagnik Bhattacharyya; Robin Wilson; Elizabeth Appiah-Kusi; Aisling O'Neill; Michael Brammer; Jesus Perez; Robin Murray; Paul Allen; Matthijs G Bossong; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

View more
  5 in total

Review 1.  Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain).

Authors:  Kevin F Boehnke; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Curr Rheumatol Rep       Date:  2022-05-03       Impact factor: 4.686

2.  Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)-A Pilot Study.

Authors:  Thorsten Rudroff; Craig D Workman; Phillip E Gander; Justin R Deters; Laura L Boles Ponto
Journal:  Brain Sci       Date:  2022-06-23

3.  Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.

Authors:  Eliud Morales Dávila; Felipe Patricio; Mariana Rebolledo-Bustillo; David Garcia-Gomez; Juan Carlos Garcia Hernandez; Brenda L Sanchez-Gaytan; Ilhuicamina Daniel Limón; Jose Manuel Perez-Aguilar
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

4.  Neuroprotective potential of Cannabis sativa-based oils in Caenorhabditis elegans.

Authors:  Ana Paula Vanin; Wagner Antonio Tamagno; Carla Alves; Letícia Mesacasa; Luciani Figueiredo Santin; Nathália Tafarel Sutorillo; Denise Bilibio; Caroline Müller; Leandro Galon; Rosilene Rodrigues Kaizer
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

5.  Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.

Authors:  Joji Suzuki; Bianca Martin; Sara Prostko; Peter R Chai; Roger D Weiss
Journal:  Integr Med Rep       Date:  2022-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.